REFERENCES
1. Fathima S, Shanmugasundaram R, Adams D, Selvaraj RK. Gastrointestinal microbiota and their manipulation for improved growth and performance in chickens. Foods. 2022;11:1401.
2. Shu LZ, Ding YD, Xue QM, Cai W, Deng H. Direct and indirect effects of pathogenic bacteria on the integrity of intestinal barrier. Ther Adv Gastroenterol. 2023;16:17562848231176427.
3. Van Hul M, Cani PD, Petitfils C, De Vos WM, Tilg H, El-Omar EM. What defines a healthy gut microbiome? Gut. 2024;73:1893-908.
4. Mohsenzadeh A, Pourasgar S, Mohammadi A, et al. The gut microbiota and cardiovascular disease: exploring the role of microbial dysbiosis and metabolites in pathogenesis and therapeutics. Life Sci. 2025;381:123981.
5. Kittana H, Gomes-Neto JC, Heck K, et al. Evidence for a causal role for escherichia coli strains identified as adherent-invasive (AIEC) in intestinal inflammation. mSphere. 2023;8:e0047822.
6. Mahdavi AH, Rahmani HR, Nili N, Samie AH, Soleimanian-Zad S, Jahanian R. Effects of dietary egg yolk antibody powder on growth performance, intestinal Escherichia coli colonization, and immunocompetence of challenged broiler chicks. Poult Sci. 2010;89:484-94.
7. Shin JH, Yang M, Nam SW, et al. Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immunol. 2002;9:1061-6.
8. Artman C, Idegwu N, Brumfield KD, et al. Feasibility of polyclonal avian Immunoglobulins (IgY) as prophylaxis against human norovirus infection. Viruses. 2022;14:2371.
9. Ibrahim El-SM, Rahman AK, Isoda R, Umeda K, Van Sa N, Kodama Y. In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY). Vaccine. 2008;26:2073-80.
10. Van Nguyen S, Umeda K, Yokoyama H, Tohya Y, Kodama Y. Passive protection of dogs against clinical disease due to Canine parvovirus-2 by specific antibody from chicken egg yolk. Can J Vet Res. 2006;70:62-4.
11. Zhu W, Zhang X, Wang D, Yao Q, Ma GL, Fan X. Simulator of the human intestinal microbial ecosystem (SHIME(®)): current developments, applications, and future prospects. Pharmaceuticals (Basel). 2024;17:1639.
12. Deyaert S, Moens F, Pirovano W, et al. Development of a reproducible small intestinal microbiota model and its integration into the SHIME(®)-system, a dynamic in vitro gut model. Front Microbiol. 2022;13:1054061.
13. De Oliveira FL, Salgaço MK, de Oliveira MT, et al. Exploring the potential of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 as promising psychobiotics using SHIME. Nutrients. 2023;15:1521.
14. Rivera Calo J, Rubinelli PM, Ricke SC. Gentamicin susceptibility and comparison of adhesion and invasion of Caco-2 and HD11 cell lines by Salmonella enterica serotypes. Appl Sci. 2024;14:3305.
15. Sivieri K, Morales ML, Adorno MA, Sakamoto IK, Saad SM, Rossi EA. Lactobacillus acidophilus CRL 1014 improved “gut health” in the SHIME reactor. BMC Gastroenterol. 2013;13:100.
16. Sato Y, Kanayama M, Nakajima S, Hishida Y, Watanabe Y. Sialyllactose enhances the short-chain fatty acid production and barrier function of gut epithelial cells via nonbifidogenic modification of the fecal microbiome in human adults. Microorganisms. 2024;12:252.
17. Pieper R, Vahjen W, Zentek J. Intestinal lactose and mineral concentration affect the microbial ecophysiology along the gastrointestinal tract of formula-fed neonatal piglets. J Anim Sci. 2016;94:3786-95.
18. Chen H, Wang Z, Zhao Y, Yang W, Huang J, Yu Z. Gut microbial ammonia enhances colonic acetylcholine levels to regulate intestinal motility. Nat Microbiol. 2026;11:907-19.
19. Duysburgh C, Verstrepen L, Van Meulebroek L, Marzorati M. Tributyrin (CoreBiome(®)) enhances butyrate levels and modulates the gut microbiota, barrier function, and immune response in vitro. Front Nutr. 2025;12:1712993.
20. Chalghoumi R, Théwis A, Beckers Y, Marcq C, Portetelle D, Schneider YJ. Adhesion and growth inhibitory effect of chicken egg yolk antibody (IgY) on Salmonella enterica serovars Enteritidis and Typhimurium in vitro. Foodborne Pathog Dis. 2009;6:593-604.
21. Deng S, Luo X, Du Y, et al. Immunoglobulin Y antibodies against colonization-related genes block the growth and infection of Helicobacter pylori. Front Immunol. 2025;16:1582250.
22. Nilsson E, Amini A, Wretlind B, Larsson A. Pseudomonas aeruginosa infections are prevented in cystic fibrosis patients by avian antibodies binding Pseudomonas aeruginosa flagellin. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;856:75-80.
23. Abbas AT, El-Kafrawy SA, Sohrab SS, Azhar EIA. IgY antibodies for the immunoprophylaxis and therapy of respiratory infections. Hum Vaccin Immunother. 2019;15:264-75.
24. Chen D, Yu J, Wang J, et al. IgY antibodies as a non-antibiotic approach to combat Vibrio vulnificus infection and gut microbiota dysbiosis in zebrafish. Fish Shellfish Immunol. 2025;166:110637.
25. Zhao S, Liu W, Wang J, et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J Mol Endocrinol. 2017;58:1-14.
26. Doi K, Mori K, Komatsu M, et al. Molecular mechanisms of complex-type N-glycan breakdown and metabolism by the human intestinal bacterium Barnesiella intestinihominis. J Biosci Bioeng. 2025;139:14-22.
27. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. Escherichia coli pathobionts associated with inflammatory bowel disease. Clin Microbiol Rev. 2019;32:10.1128/cmr.00060-18.
28. Li X, Yao Y, Wang X, et al. Chicken egg yolk antibodies (IgY) modulate the intestinal mucosal immune response in a mouse model of Salmonella typhimurium infection. Int Immunopharmacol. 2016;36:305-14.
29. Wang Z, Li J, Li J, et al. Protective effect of chicken egg yolk immunoglobulins (IgY) against enterotoxigenic Escherichia coli K88 adhesion in weaned piglets. BMC Vet Res. 2019;15:234.
30. Ma X, Li M, Zhang Y, et al. Akkermansia muciniphila identified as key strain to alleviate gut barrier injury through Wnt signaling pathway. eLife. 2025;12:RP92906.
31. Liu X, Wang L, Huang B, Jiao Y, Guan Y, Nuli R. Barnesiella intestinihominis improves gut microbiota disruption and intestinal barrier integrity in mice with impaired glucose regulation. Front Pharmacol. 2025;16:1635579.
32. Yan H, Ajuwon KM. Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PLoS ONE. 2017;12:e0179586.
33. Mafi M, Rezaei Adriani R, Mohammadkhani F, Mousavi Gargari SL. Development of protective egg yolk immunoglobulins (IgY) targeting CfaB, LTB, and EtpA recombinant proteins of Enterotoxigenic Escherichia coli (ETEC) for inhibiting toxin activity and bacterial adherence. Braz J Microbiol. 2025;56:403-13.
